Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Breast 1

Conditions

Prostatic Neoplasms 1Non-small Cell Lung Cancer Adenocarcinoma 1Disease Progression 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

tremelimumab 1pembrolizumab 1grapiprant 1durvalumab 1cemiplimab 1brigatinib 1binimetinib 1Thioctic Acid 1Standard of Care 1Sevoflurane 1Propofol 1Practice Guidelines as Topic 1Pemetrexed 1Palliative Care 1Paclitaxel 1Interleukin-2 1Gemcitabine 1Drug Therapy 1Cisplatin 1Carboplatin 1Anesthesia, Inhalation 1AZD 6244 13-fluoro-2-(4-((2-nitro-1H-imidazol-1-yl)methyl)-1H-1,2,3-triazol-1-yl)propan-1-ol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Disease Progression × grapiprant × Thoracic × Clear all
NCT02538432 2019-11-04

Phase II Trial of EP4 Receptor Antagonist, AAT-007 (RQ-07; CJ-023,423) in Advanced Solid Tumors

University of Maryland, Baltimore

Phase 2 Withdrawn
BreastGenitourinaryThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Prostatic Neoplasms, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡